Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Muscadine Grape Seed Supplementation and Vascular Function

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
StatusAvslutad
Sponsorer
Wake Forest University Health Sciences

Nyckelord

Abstrakt

The investigators sought to evaluate the effect of muscadine grape seed supplementation on brachial diameter and flow-mediated vasodilator responses in subjects with, or at risk for cardiovascular disease.
Methods: In a randomized, double-blind, placebo-controlled crossover trial, 50 adults (25 men, 25 women) with one or more cardiac risk factors were randomized to muscadine grape seed (MGS) supplement 1300mg daily vs.. placebo for 4 weeks each, with a 4-week washout between study periods. Resting diameter and endothelial function measured using brachial flow-mediated dilation (FMD) were determined at the beginning and end of each study period.

Beskrivning

Study Participants Participants were adult male and non-pregnant female outpatients ages 18-65 with one or more of the following cardiovascular risk factors: hypertension (blood pressure ≥ 140/90 or current treatment for hypertension); dyslipidemia (total cholesterol > 220 mg/dL + LDL cholesterol > 130 mg/dL, or current use of lipid-lowering medications); or controlled type 2 diabetes mellitus (glycated hemoglobin < 8.0 % with or without medication). Subjects with a history of coronary artery disease (any history of myocardial infarction or coronary revascularization) were also eligible for participation. Subjects were excluded if they had a history of congestive heart failure (any classification), unstable angina or acute coronary syndrome within the last 30 days, uncontrolled hypertension (blood pressure ≥ 170/100 mm/Hg), type 1 diabetes mellitus, uncontrolled type 2 diabetes mellitus (HbA1C ≥ 8.0%), history of gastrointestinal disease or surgery affecting absorption, peripheral arterial disease, diagnosis of active cancer (excluding squamous cell or basal cell skin cancer), current use of long-acting nitrate compounds such as isosorbide dinitrate or nitroglycerin, recent change in any medications (last 30 days), active plan to change diet or exercise patterns, history of hypersensitivity to any compound in the intervention or placebo, or history of intolerance to nitrates.

Study Design The study was a double-blind, randomized crossover design to evaluate the effects of muscadine grape seed supplementation (Nature's Pearl 650 mg, two capsules daily.) The phytochemical profile of the supplement is presented in Table 1. The trial consisted of a screening visit followed by baseline and closeout visits for two study treatment periods (4 weeks each), separated by a 4-week washout period (total of 5 visits over 14 weeks).Endothelial function was assessed at the beginning and end of each study period using brachial artery flow-mediated dilation (brachial FMD - described below). A fasting blood sample was obtained at the open and close of each study period for measurement of lipids, inflammatory markers, and markers of antioxidant capacity and oxidative stress. Participants were asked to abstain from red wine, antioxidant vitamin supplements (including vitamin E, vitamin C, and beta-carotene supplements, more than 1 cup of black or green tea daily, and other grape seed supplements. Multivitamin supplements were permitted as long as they were taken for the study duration.

Endothelial Function Study Protocol Details for the brachial FMD protocol, automated analysis and reproducibility have been published previously {Herrington 2001}. Briefly, subjects rested in a quiet, temperature-controlled room for 15 minutes. A standard (pediatric) cuff was placed on the right forearm 2 inches (5 cm) below the antecubital fossa. Once the transducer position was established over the left brachial artery, continuous scanning of the brachial artery was obtained for 2 minutes before the cuff occlusion, 4 minutes of cuff occlusion, and 2 minutes immediately after cuff release. Data were analyzed with an automated analysis system that determines changes in brachial artery diameter for 2 minutes after cuff release.

Statistical Analysis The effects of supplementation with muscadine grape seeds and placebo were compared using paired t-tests and mixed linear models to take into account treatment order and period effects. The mixed linear models were also used to formally test for a residual effect of treatment in those subjects receiving active treatment in the first treatment period. Stratified analyses were performed to look for evidence of differential effects by age, gender, prevalent heart disease or heart disease risk factors. Nominal 2-tailed p-values are presented for the primary outcome (percent change in brachial diameter) and for all secondary outcomes. All analyses were performed using SAS v. 9.1 (Cary, NC).

Datum

Senast verifierad: 07/31/2018
Först skickat: 11/09/2009
Beräknad anmälan inlämnad: 11/09/2009
Först publicerad: 11/10/2009
Senaste uppdatering skickad: 08/06/2018
Senaste uppdatering publicerad: 08/08/2018
Faktiskt startdatum för studien: 05/31/2007
Uppskattat primärt slutdatum: 11/30/2007
Beräknat slutfört datum: 08/31/2008

Tillstånd eller sjukdom

Dietary Supplements

Intervention / behandling

Dietary Supplement: Muscadine grape seed supplement

Fas

-

Armgrupper

ÄrmIntervention / behandling
Experimental: grape seed supplement
Nature's Pearl 650 mg, two capsules daily
Placebo Comparator: placebo
placebo

Urvalskriterier

Åldrar berättigade till studier 18 Years Till 18 Years
Kön som är berättigade till studierAll
Accepterar friska volontärerJa
Kriterier

Inclusion Criteria:

- adult male and non-pregnant female outpatients, with

- hypertension (blood pressure ≥ 140/90 or current treatment for hypertension), or

- dyslipidemia (total cholesterol > 220 mg/dL + LDL cholesterol > 130 mg/dL, or current use of lipid-lowering medications), or

- controlled type 2 diabetes mellitus (glycated hemoglobin < 8.0 % with or without medication).

Exclusion Criteria:

- history of congestive heart failure (any classification)

- unstable angina or acute coronary syndrome within the last 30 days,

- uncontrolled hypertension (blood pressure ≥ 170/100 mm/Hg),

- type 1 diabetes mellitus,

- uncontrolled type 2 diabetes mellitus (HbA1C ≥ 8.0%),

- history of gastrointestinal disease or surgery affecting absorption,

- peripheral arterial disease,

- diagnosis of active cancer (excluding squamous cell or basal cell skin cancer),

- current use of long-acting nitrate compounds such as isosorbide dinitrate or nitroglycerin,

- recent change in any medications (last 30 days),

- active plan to change diet or exercise patterns,

- history of hypersensitivity to any compound in the intervention or placebo,

- history of intolerance to nitrates

Resultat

Primära resultatåtgärder

1. Brachial Artery Flow mediated dilation [1 month]

Sekundära resultatåtgärder

1. Plasma markers of inflammation and anitoxidant capacity [1 month]

Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge